The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.
In combination with platinum and 5‑fluorouracil (5‑FU) chemotherapy is indicated for the first‑line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express PD‑L1 with a CPS ≥ 1KEYNOTE-048
Head and neck cancer
Squamous cell
CPS PD-L1 expression ≥1
KEYNOTE-048
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Brigatinib
-
Crizotinib
Treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) previously not treated with an ALK inhibitorALTA-1L
Thoracic Malignancies
Non-small-cell Lung Cancer
ALK+
ALTA-1L
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Encorafenib
Cetuximab
Either irinotecan or FOLFIRI with cetuximab
Treatment of patients with mCRC with a BRAF V600E mutation, who have received prior systemic therapy BEACON CRC
Gastrointestinal Cancers
Colorectal Cancer
BRAF V600E
BEACON CRC
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Avelumab
Best supportive care
Best supportive care
First-line maintenance treatment of adult patients who are progression-free following platinum-based ChTJAVELIN Bladder 100
Genitourinary Cancers
Urothelial Carcinoma
-
JAVELIN Bladder 100
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Nivo/Ipi (nivolumab and ipilimumab)
-
Chemotherapy
First-line treatment for patients with mNSCLC expressing PD-L1 (≥1%) with no EGFR or ALK genomic tumour aberrationsCheckMate 227
Thoracic Malignancies
Non-small-cell Lung Cancer
PD-L1 ≥1%
CheckMate 227
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Nivolumab
-
Taxane ChT docetaxel or paclitaxel
Recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine and platinum-based ChTATTRACTION-3
Gastrointestinal Cancers
Oesophageal Cancer
-
ATTRACTION-3
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Pembrolizumab
ChT
Placebo plus ChT
Treatment of locally recurrent unresectable or metastaticTNBC in adults whose tumours express PD-L1 with a CPS ≥ 10 and who have not received prior chemotherapy KEYNOTE-355
Breast Cancer
Breast Cancer
Triple-negative, PD-L1 (CPS ≥10)
KEYNOTE-355
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Trastuzumab deruxtecan
-
ChT (irinitecan or paclitaxel)
Treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma in patients who have received a prior trastuzumab-based regimenDESTINY-Gastric01
Gastrointestinal Cancers
Gastric or gastroesophageal junction adenocarcinoma
HER2+
DESTINY-Gastric01
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Avelumab
-
Single arm
Adult patients with metastatic Merkel cell carcinoma (MCC)JAVELIN Merkel 200 (Part A - pretreated patients)
Skin Cancers
Merkel cell carcinoma
-
JAVELIN Merkel 200 (Part A - pretreated patients)
4
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
4
Cemiplimab
-
Platinum based ChT (Crossover allowed)
First-line locally advanced NSCLC who are not candidates for definitive chemoradiation or metastatic NSCLCEMPOWER-Lung 1
Thoracic Malignancies
Non-small-cell Lung Cancer
PD-L1>50% negative EGFR, ALK or ROS1
EMPOWER-Lung 1
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Nivo/Ipi (nivolumab and ipilimumab)
2 cycles of platinum-based ChT
Chemotherapy
First line treatment of mNSCLC with no sensitising EGFR mutation or ALK translocation CheckMate-9LA
Thoracic Malignancies
Non-small-cell Lung Cancer
-
CheckMate-9LA
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Enzalutamide
ADT (androgen deprivation therapy)
Placebo + ADT
For the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapyARCHES
Genitourinary Cancers
Prostate cancer
-
ARCHES
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Lorlatinib
-
Crizotinib
Treatment of adult patients with anaplastic lymphoma kinase (ALK) positive (NSCLC) previously not treated with an ALK inhibitor CROWN
Thoracic Malignancies
Non-small-cell Lung Cancer
ALK+
CROWN
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Pembrolizumab
-
Investigator’s choice of ChT (paclitaxel, docetaxel or vinflunine)
Locally advanced or metastatic UC in adults who have received prior platinum-containing ChTKEYNOTE-045
Genitourinary Cancers
Urothelial Carcinoma
-
KEYNOTE-045
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Lenvatinib
Pembrolizumab
Sunitinib
Treatment of adults with advanced renal cell carcinoma in combination with pembrolizumab as first-line treatmentCLEAR
Genitourinary Cancers
Renal cell cancer
-
CLEAR
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Enfortumab vedotin
-
Investigator-chosen ChT (standard docetaxel, paclitaxel or vinflunine)
Treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand 1 inhibitorEV-301
Genitourinary Cancers
Urothelial Carcinoma
-
EV-301
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Nivolumab
Fluoropyrimidine and platinum ChT (FOLFOX or CAPOX)
ChT (FOLFOX or CAPOX)
First‑line treatment for patients with HER2‑negative advanced or metastatic gastric, gastroesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a CPS ≥5CheckMate 649
Gastrointestinal Cancers
Gastric or gastroesophageal junction cancer and oesophageal adenocarcinoma
HER2- PD-L1 CPS ≥5
CheckMate 649
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Pembrolizumab
-
ChT ((5-fluorouracil–based therapy with or without bevacizumab or cetuximab)
First-line treatment of adults with MSI-H or dMMR mCRCKEYNOTE-177
Gastrointestinal Cancers
Colorectal Cancer
dMMR or MSI-H
KEYNOTE-177
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Pembrolizumab
ChT with our without bevacizumab
Placebo + ChT with our without bevacizumab
Persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS ≥1 KEYNOTE-826
Gynaecological Malignancies
Cervical Cancer
PD-L1 (CPS ≥1)
KEYNOTE-826
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Pembrolizumab
Platinum and fluoropyrimidine-based chemotherapy
Placebo + cisplatin and 5-FU
Pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus in adults whose tumours express PD-L1 with a CPS ≥ 10KEYNOTE-590
Gastrointestinal Cancers
Oesophageal Cancer
PD-L1 CPS ≥10
KEYNOTE-590
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Pembrolizumab
Cisplatin and 5-FU ChT
Placebo + cisplatin and 5-FU ChT
First-line treatmentKEYNOTE-590
Gastrointestinal Cancers
Oesophageal or gastroesophageal carcinoma
HER2- GEJ PD-L1 (squamous cell) CPS ≥10
KEYNOTE-590
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Tebentafusp
-
Investigator Choice (either dacarbazine, ipilimumab or pembrolizumab)
Treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanomaIMCgp100-202
Skin Cancers
Uveal melanoma
HLA-A*0201positive
IMCgp100-202
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Relugolix
-
Leuprolide
Adult patients with advanced hormone-sensitive prostate cancerHERO
Genitourinary Cancers
Prostate cancer
-
HERO
4
PRELIMINARY SCORE
NI
ADJUSTMENTS
FINAL SCORE
F2c
4
Nivo/Ipi (nivolumab and ipilimumab)
-
ChT
First-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥1%CheckMate 648
Gastrointestinal Cancers
Oesophageal Cancer
PD-L1 expression ≥1%
CheckMate 648
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Nivolumab
Fluoropyrimidine and platinum-based combination ChT
ChT
First-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥1%CheckMate 648
Gastrointestinal Cancers
Oesophageal Cancer
PD-L1 expression ≥1%
CheckMate 648
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Pembrolizumab
-
Ipilimumab
Treatment of adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanomaKEYNOTE-006
Skin Cancers
Cutaneous Melanoma
-
KEYNOTE-006
A
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a/F1
4
A
177Lu-PSMA-617
Best standard of care (restricted)
Best standard of care (restricted)
In combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with AR pathway inhibition and taxane based chemotherapy.VISION
Genitourinary Cancers
Prostate cancer
PSMA-positive mCRPC
VISION
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Pembrolizumab
Lenvatinib
Treatment of physician's choice (doxorubicin or paclitaxel)
Patients with advanced or recurrent endometrial carcinoma who have progressed following prior platinum-containing therapy in any setting and who are not candidates for curative surgery or RTKEYNOTE-775
Gynaecological Malignancies
Endometrial Cancer
-
KEYNOTE-775
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Pembrolizumab
Lenvatinib
Treatment of physician's choice (doxorubicin or paclitaxel)
Patients with advanced endometrial carcinoma that is not MSI-H or dMMR, who have disease progression following prior systemic therapy and are not candidates for curative surgery or RTKEYNOTE-775
Gynaecological Malignancies
Endometrial Cancer
-
KEYNOTE-775
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Watchlist
Tested Agent(s)
Combined Agent(s)
Control Arm
Therapeutic Indication
Tumour Type
Tumour Sub-type
Tumour Sub-group
Trial Name
Ref.
Score
Scorecard
Scorecard
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.